Opposing roles of eosinophils in cancer

Simon, Sonja C. S.; Utikal, Jochen; Umansky, Viktor

doi:10.1007/s00262-018-2255-4

Cited by 97 publications

(115 citation statements)

References 101 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Moreover, this observation is also supported by reports of an association between elevated eosinophil counts, better clinical responses and longer overall survival in several types of advanced cancer; this association might be stronger and more clinically relevant for patients treated with ICIs than with conventional chemotherapy. [8][9][10][11][13][14][15][16][17] Considering that eosinophils can have a role in the response against cancer, [17][18][19][20] an elevated AEC might be a marker of effectiveness in some patients. Further research is needed to determine the mechanisms involved in Eo-ir, the clinical significance of high blood eosinophilia on cancer outcome, and whether eosinophils are involved in ICIT effectiveness or just a reactive "biological" phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“…Further research is needed to determine the mechanisms involved in Eo-ir, the clinical significance of high blood eosinophilia on cancer outcome, and whether eosinophils are involved in ICIT effectiveness or just a reactive "biological" phenomenon. 17,21 Given its retrospective design, our study had several inherent limitations: misclassification, missing data, and the risk of selection bias due to the FPVD's self-reporting procedure (emphasizing the most symptomatic cases). However, this case series enabled to consider differential diagnoses and the management of Eo-irAEs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

et al. 2020

View full text Add to dashboard Cite

A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4─139] weeks. The median AEC was 2.7 [0.8─90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As in other immunological disease settings, the role of eosinophils in cancer is diverse and microenvironment dependent . Eosinophils have been identified in several cancers of both epithelial and nonepithelial origin, including pancreatic cancer, glioblastoma, bladder, cervical, colorectal cancer, as well as melanoma and lymphoma.…”

Section: Eosinophils In Cancermentioning

confidence: 99%

“…As in other immunological disease settings, the role of eosinophils in cancer is diverse and microenvironment dependent. [33][34][35] Eosinophils have been identified in several cancers of both epithelial and nonepithelial origin, including pancreatic cancer, glioblastoma, bladder, cervical, colorectal cancer, as well as melanoma and lymphoma. The presence of tumor-associated tissue eosinophils as a prognostic indicator of disease outcome varies significantly as eosinophils have been shown to have both pro-or anti-tumorigenic functions.…”

Section: Eos Inophil S In C An Cermentioning

confidence: 99%

Deciphering the role of eosinophils in solid organ transplantation

Onyema

Guo

Hata

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

Eosinophils are rare granulocytes that belong to the innate arm of the immune system. This cell population is traditionally defined as a destructive and cytotoxic mediator in asthma and helminth infection. Limited data in transplantation have suggested that eosinophils play a similar role in potentiating deleterious organ inflammation and immunologic rejection. Contrary to this long‐held notion, recent data have uncovered the possibility that eosinophils play an alternative role in immune homeostasis, defense against a wide range of pathogens, as well as downregulation of deleterious inflammation. Specifically, translational data from small animal models of lung transplantation have demonstrated a critical role for eosinophils in the downregulation of alloimmunity. These findings shed new light on the unique immunologic features of the lung allograft and demonstrate that environmental polarization may alter the phenotype and function of leukocyte populations previously thought to be static in nature. In this review, we provide an update on eosinophils in the homeostasis of the lung as well as other solid organs.

show abstract

“…Eosinophils are not only a source of numerous cytokines and growth factors, but they also display both proinflammatory and anti-inflammatory activities, as well as immunoregulatory ones, which are most likely regulated by a complex network determined by surface molecules, extracellular components, and cell-cell interactions [28][29][30][31][32][33]. The role of eosinophils in allergic diseases led to several studies of the association between allergic conditions and cancer incidence [34,35]. Interestingly, these reported an inverse relationship between allergy-based diseases and several malignancies, including lung cancer, colorectal cancer, prostate cancer, breast cancer, and pancreatic cancer [36][37][38][39][40][41][42][43][44].…”

Section: Introductionmentioning

confidence: 99%

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

et al. 2020

View full text Add to dashboard Cite

Background: The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Blood and tissue biomarkers to identify responders and long-term survivors and to optimize cost and cost-effectiveness of treatment are greatly needed. We wanted to investigate whether blood eosinophilia is a predictive biomarker for patients with solid tumors receiving vaccinations with DCs loaded with autologous tumor-RNA. Methods: In total, 67 patients with metastatic solid tumors, who we treated with autologous monocyte-derived DCs transfected with total tumor mRNA, were serially analyzed for eosinophil counts and survival over the course of up to 14 years. Eosinophilic counts were performed on peripheral blood smears. Results: Up to 87% of the patients treated with DC-based immunotherapy experienced at least once an eosinophilia of ≥ 5% after initiation of therapy; 61 % reached levels of ≥ 10% eosinophils, and 13% of patients showed eosinophil counts of 20% or above. While prevaccination eosinophil levels were not associated with survival, patients with blood eosinophilia at any point after initiation of DC-based immunotherapy showed a trend towards longer survival. There was a statistically significant difference for the patients with eosinophil counts of 20% or more (p = 0.03). In those patients, survival was prolonged to a median of 58 months (range 2–111 months), compared to a median of 20 months (range 0–119 months) in patients with lower eosinophil counts. In 12% of the patients, an immediate increase in eosinophil count of at least 10 percentage points could be detected after the first vaccine, which also appeared to correlate with survival (65 vs. 24 months; p = 0.06). Conclusion: Blood eosinophilia appears to be an early, on-therapy biomarker in patients with solid tumors undergoing vaccination with RNA-transfected DC, specifically autologous tumor mRNA-transfected DC vaccines, and it correlates with long-term patient outcome. Eosinophilia should be systematically investigated in future trials.

show abstract

Opposing roles of eosinophils in cancer

Cited by 97 publications

References 101 publications

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Deciphering the role of eosinophils in solid organ transplantation

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA

Contact Info

Product

Resources

About